MedTrace Logo

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

NCT05848999 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2023-05-12

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.

Conditions

  • Mesothelin-positive Advanced Malignant Solid Tumors

Interventions

BIOLOGICAL

UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)

D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia Fang, M.D. · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2025-05-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05848999 on ClinicalTrials.gov